Adaptimmune Therapeutics plc announced that it has augmented its manufacturing leadership to prepare for clinical and commercial scale up with the additions of William Buecheler as Vice President, Manufacturing Operations, and Phil Bassett as Head of Process Development. Mr. Buecheler is responsible for Adaptimmune's global manufacturing operations, including contract and in-house manufacturing activities, and is leading the implementation of scale up plans designed to achieve commercial manufacturing capability. Mr. Bassett is responsible for process development activities including leading Adaptimmune's T-cell and lentivirus process development.

Bill Buecheler brings to Adaptimmune over 25 years of industry experience in manufacturing operations, facility planning and expansion, leadership of FDA pre-approval inspection and document preparation, and manufacturing process improvements. He joins Adaptimmune from Novartis Pharmaceuticals, where he acted as the Director and Process Unit Head, with responsibility for overall manufacturing operations of the Cell and Gene Therapy Process Unit. Phil Bassett brings with him over 15 years of process manufacturing experience in CMO, small biotech and large biopharma environments.

Most recently, Mr. Bassett served as Head of Manufacturing Development for the Cell Therapy Catapult, where he was responsible for technology transfer and providing late stage commercial manufacturing, scale-up and process industrialization expertise.